



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/147,443	01/21/1999	ANDREAS MORELL	P63221US0 1730		
7590 08/06/2004			EXAMINER		
BETH A BURROUS			VANDERVEGT, FRANCOIS P		
FOLEY & LA	RDNER				
WASHINGTO	N HARBOUR	ART UNIT	PAPER NUMBER		
3000 K STREET NW SUITE 500			1644		
WASHINGTON, DC 20007-5143			DATE MAILED: 08/06/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		, Application N	0.	Applicant(s)				
Office Action Summary		09/147,443		MORELL ET AL.				
		Examiner		Art Unit				
		F. Pierre Vand	•	1644				
Period fo	The MAILING DATE of this communication a r Reply	appears on the cov	er sheet with the c	orrespondence ad	ldress			
THE N - Exten after S - If the - If NO - Failur Any re	DRTENED STATUTORY PERIOD FOR REIMAILING DATE OF THIS COMMUNICATION IS COMMUNICATION IN COMM	N. R.1.136(a). In no event, ho reply within the statutory r iod will apply and will expitature, cause the application	owever, may a reply be tim minimum of thirty (30) days re SIX (6) MONTHS from to n to become ABANDONED	nely filed s will be considered timel the mailing date of this c O (35 U.S.C. § 133).	ly. ommunication.			
Status								
1)⊠	Responsive to communication(s) filed on 06	6 May 2004.						
2a) <u></u> □	This action is FINAL. 2b)⊠ This action is non-final.							
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
5)⊠ 6)⊠ 7)⊠	Claim(s) 22,23 and 25-44 is/are pending in 4a) Of the above claim(s) 44 is/are withdraw Claim(s) 22,23 and 25-32 is/are allowed. Claim(s) 33 and 36-43 is/are rejected. Claim(s) 34 and 35 is/are objected to. Claim(s) are subject to restriction and	vn from considerat						
Application	on Papers							
9)[[] 7	The specification is objected to by the Exam	iner.						
10) 🗌 🗀	10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	nder 35 U.S.C. § 119							
a)[	Acknowledgment is made of a claim for foreignal.  All b) Some * c) None of:  1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the priority docume application from the International Bure ee the attached detailed Office action for a least	ents have been red ents have been red riority documents eau (PCT Rule 17	ceived. ceived in Application have been receive .2(a)).	on No d in this National	Stage			
Attaches = = 4	(6)							
Attachment 1) Notice	(s) e of References Cited (PTO-892)	41 T	Interview Summary (	PTO-413)				
2) 🔲 Notice 3) 🔯 Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/(No(s)/Mail Date <u>05062004</u> .	08) 5)	Paper No(s)/Mail Da  Notice of Informal Pa  Other:	te	O-152)			

Application/Control Number: 09/147,443

Art Unit: 1644

# **DETAILED ACTION**

This application is a rule 371 continuation of PCT Serial Number PCT/EP97/03253.

Claims 1-21 and 24 have been canceled.

Claims 22, 23, and 25-44 are currently pending.

### Election/Restrictions

1. Applicant's election without traverse of Group I, claims 22-32, in the Paper filed October 22, 2003 is again acknowledged.

Upon further review the restriction requirement between Groups I & II is hereby withdrawn. In view of the fact that the recited heavy chain segments and recited light chain segments overlap in the claims, both the heavy chain and light chain sequences must be searched. Accordingly, no further burden is required to search the invention of Group II, claims 33-43, along with that of Group I.

Applicant's election without traverse of the light chain species defined as SEQ ID NO: 60 is acknowledged. Upon further review the species requirement is withdrawn.

2. Claim 44 stands withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the Paper filed October 22, 2003.

Accordingly, claims 22, 23 and 25-43 are the subject of examination in the present Office Action.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. Claims 33 and 36-43 are rejected under 35 U.S.C. 102(b) as being anticipated by Dziegiel et al (J. Imm. Meth. [1995] 182:7-19; AO on form PTO-1449 filed March 1, 1999, of record).

Dziegiel teaches a purified polypeptide that binds to the rhesus D erythrocyte surface antigen (Abstract in particular). Dziegiel teaches that the polypeptide is an Fab fragment [claim 36] of an immunoglobulin comprising both V<sub>H</sub> and V<sub>L</sub> regions that specifically binds to Rhesus D antigen (page 10, paragraph bridging columns in particular)[claim 37]. Accordingly, the polypeptide satisfies the metes and

Art Unit: 1644

bounds of the limitation in claim 33 that the polypeptide is "a functional variant" of SEQ ID NO: 60. Applicant is reminded that the "function" of any antibody is to bind to an antigen. Accordingly, any antibody that binds to rhesus D antigen polypeptide satisfies the metes and bounds of the limitation "functional variant" in the claim. Dziegiel teaches that the antibody was engineered from a monoclonal human antibody of the IgG1 subclass (page 10, paragraph bridging columns in particular)[claim 38]. Dziegiel teaches that the nucleic acid sequences encoding the immunoglobulin fragment were obtained using standard methods (page 14, first paragraph of first column in particular)[claim 39]. Dziegel teaches the formulation of the Fab polypeptides in phosphate-buffered saline, a pharmaceutically acceptable carrier (page 14, second paragraph of first column in particular)[claims 40-41]. Dziegiel teaches that the Fab can be used for typing rhesus D antigen (Table 4 in particular)[claims 42-43]. The prior art teaching anticipates the claimed invention.

#### Conclusion

- 4. Claims 34 and 35 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- 5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (571) 272-0852. The examiner can normally be reached on M-Th 6:30-4:00; Alternate Fridays 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

F. Pierre VanderVegt, Ph.D.

Patent Examiner August 4, 2004 PATRICK J. NOLAN, PH.D PRIMARY EXAMINER